Screener
ResMed RMD Ratios & Valuation
| Q4 '26 | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 61.1%+1.7pp | 61.6%+2.8pp | 60.9%+2.5pp | 60.1%+2.4pp | 59.4%+2.7pp | |
| Operating margin | 33.4%+0.6pp | 34.2%+2.1pp | 33.7%+2.0pp | 33.2%+3.7pp | 32.7%+4.6pp | |
| Net margin | 26.9%-0.3pp | 27.4%+1.3pp | 27.5%+2.2pp | 27.4%+4.2pp | 27.2%+5.4pp | |
| Returns | ||||||
| Return on equity | 24.3%-1.6pp | 25.2%-0.6pp | 25.7%0.0pp | 25.4%+1.8pp | 25.9%+3.2pp | |
| Return on invested capital | 25.9%+0.6pp | 26.5%+2.2pp | 25.6%+3.1pp | 25.1%+4.6pp | 25.3%+5.9pp | |
| Efficiency | ||||||
| Asset turnover | 0.7×0.0× | 0.7×0.0× | 0.7×0.0× | 0.7×0.0× | 0.7×0.0× | |
| Liquidity | ||||||
| Current ratio | 3.1×-0.3× | 3×-0.4× | 3.1×-0.3× | 2.9×0.0× | 3.4×+0.9× | |
| Leverage | ||||||
| Debt-to-equity | 0.1×0.0× | 0.2×0.0× | 0.2×0.0× | 0.2×0.0× | 0.1×0.0× | |
| Per Share | ||||||
| Book value per share | $45.42+12.1% | $44.55+18.3% | $43.18+21.2% | $41.67+18.4% | $40.50+22.9% | |
| Valuation | ||||||
| Market capitalization | $32.38B-21.3% | $32.7B-0.5% | $35.16B+4.7% | $40.08B+11.7% | $37.52B+33.4% | |
| Price / earnings | 21.3×-8.1× | 21.5×-3.5× | 23.7×-3.2× | 27.9×-4.4× | 26.8×-0.8× | |
| Price / sales | 5.7×-2.3× | 5.9×-0.6× | 6.5×-0.3× | 7.6×+0.2× | 7.3×+1.3× | |
| Price / book | 4.9×-2.0× | 5×-0.9× | 5.6×-0.8× | 6.5×-0.4× | 6.3×+0.5× | |
| Dividend yield | 0.5%-0.2pp | 1%+0.1pp | 0.9%+0.1pp | 0.8%0.0pp | 0.8%-0.2pp |
FAQ
- What are ResMed's profit margins?
- ResMed (RMD) runs a 61.1% gross margin and a 33.4% operating margin, with a 26.9% net margin.
- Where do ResMed's ratios come from?
- Every ratio is computed from ResMed's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
